2Remme WJ. For the task force of the working group of heart failure of the European Society of Cardiology: the treatment of heart failure.Eur Heart J, 1997:736-753.
4Banatvala N, Griffin P M , Greene K D, et al. The United States national prospective hemolytic uremic syndrome: microbiologic,serologic, clinical, and epidemiologic findings. JID, 2001,183:1063-1070.
5Vesely SK, George JN, Laramie B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpum-hemolytic uremic syndrome:relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 2003 , 102:60-68.
6George JN. The association of pregnancy with thrombotic thrombocytopenic purpum-hemolytic uremic syndrome. Curr Opin Hematol, 2003,10:339-344.
7Studt JD, Kremer Hovinga JA, Alberio L, et al. yon Willebrand factor -cleaving protease (ADAMTS13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Med Wkly, 2003,133(23-24) :325-332.
二级参考文献8
1Myones BL, McCurdy D. The antiphospholipid syndrome: immunologic and clinical aspects. Clinical spectrum and treatment. J Rheumatol, 2000, 27 Suppl 58: 20-28.
2Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum, 1999, 42: 1309-1311.
3Piette JC, Cacoub P, Wechsler B. Renal manifestations of the antiphospholipid syndrome. Semin Arthritis Rheum, 1994, 23: 357-366.
4Amigo MC, Khamashta MA. Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am, 2000, 26: 331-348.
5Amigo MC, Khamashta MA, Hughes GR. Antiphospholipid syndrome in SLE. Baillieres Clin Rheumatol, 1998, 12: 477-493.
6Vila LM, Mayor AM, Valentin AH, et al. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus, 2000, 9: 110-115.
